ArchPoint Investors’s Guardant Health GH Stock Holding History

ArchPoint Investors’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,215	Closed	-$882K	–	135
2019 Q2	$882K	Buy	+10,215	New	+$780K	0.28%	35

Other funds holding GH

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ArchPoint Investors's GH Position: Q3 2019 in Review

ArchPoint Investors sold out of Guardant Health (GH) in Q3 2019, closing a stake of 10,215 shares — an estimated $882K sold.

ArchPoint Investors first reported a position in GH in Q2 2019 and held it in 1 quarter. The position peaked at $882K in Q2 2019. 242 funds tracked by Wall St. Rank hold GH as of Q3 2019.

ArchPoint Investors reported no remaining Guardant Health position as of Q3 2019 after selling out during the quarter.
ArchPoint Investors sold 10,215 Guardant Health shares in Q3 2019, an estimated $882K.
ArchPoint Investors first reported a position in Guardant Health in Q2 2019 and held it in 1 quarter.
ArchPoint Investors's Guardant Health position peaked at $882K in Q2 2019.
242 funds tracked by Wall St. Rank held Guardant Health as of Q3 2019.

Based on ArchPoint Investors's 13F filing for Q3 2019, filed 13 Nov 2019.